These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 33887686)

  • 21. Successful creation of pancreatic cancer organoids by means of EUS-guided fine-needle biopsy sampling for personalized cancer treatment.
    Tiriac H; Bucobo JC; Tzimas D; Grewel S; Lacomb JF; Rowehl LM; Nagula S; Wu M; Kim J; Sasson A; Vignesh S; Martello L; Munoz-Sagastibelza M; Somma J; Tuveson DA; Li E; Buscaglia JM
    Gastrointest Endosc; 2018 Jun; 87(6):1474-1480. PubMed ID: 29325707
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Organoid technology and applications in cancer research.
    Xu H; Lyu X; Yi M; Zhao W; Song Y; Wu K
    J Hematol Oncol; 2018 Sep; 11(1):116. PubMed ID: 30219074
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Patient-Derived Tumor Organoids Can Predict the Progression-Free Survival of Patients With Stage IV Colorectal Cancer After Surgery.
    Wang T; Tang Y; Pan W; Yan B; Hao Y; Zeng Y; Chen Z; Lan J; Zhao S; Deng C; Zheng H; Yan J
    Dis Colon Rectum; 2023 May; 66(5):733-743. PubMed ID: 36898057
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of Cell and Organoid-Level Analysis of Patient-Derived 3D Organoids to Evaluate Tumor Cell Growth Dynamics and Drug Response.
    Kim S; Choung S; Sun RX; Ung N; Hashemi N; Fong EJ; Lau R; Spiller E; Gasho J; Foo J; Mumenthaler SM
    SLAS Discov; 2020 Aug; 25(7):744-754. PubMed ID: 32349587
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects and Eradication of Mycoplasma Contamination on Patient-derived Colorectal Cancer Organoid Cultures.
    Dayanidhi DL; Watlington WK; Mantyh JB; Rupprecht G; Hsu DS
    Cancer Res Commun; 2023 Sep; 3(9):1952-1958. PubMed ID: 37772998
    [TBL] [Abstract][Full Text] [Related]  

  • 26. OrBITS: label-free and time-lapse monitoring of patient derived organoids for advanced drug screening.
    Deben C; De La Hoz EC; Compte ML; Van Schil P; Hendriks JMH; Lauwers P; Yogeswaran SK; Lardon F; Pauwels P; Van Laere S; Bogaerts A; Smits E; Vanlanduit S; Lin A
    Cell Oncol (Dordr); 2023 Apr; 46(2):299-314. PubMed ID: 36508089
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Head and neck cancer organoids established by modification of the CTOS method can be used to predict in vivo drug sensitivity.
    Tanaka N; Osman AA; Takahashi Y; Lindemann A; Patel AA; Zhao M; Takahashi H; Myers JN
    Oral Oncol; 2018 Dec; 87():49-57. PubMed ID: 30527243
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Plocabulin Displays Strong Cytotoxic Activity in a Personalized Colon Cancer Patient-Derived 3D Organoid Assay.
    Costales-Carrera A; Fernández-Barral A; Bustamante-Madrid P; Guerra L; Cantero R; Barbáchano A; Muñoz A
    Mar Drugs; 2019 Nov; 17(11):. PubMed ID: 31752287
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genomic characteristics and drug screening among organoids derived from non-small cell lung cancer patients.
    Chen JH; Chu XP; Zhang JT; Nie Q; Tang WF; Su J; Yan HH; Zheng HP; Chen ZX; Chen X; Song MM; Yi X; Li PS; Guan YF; Li G; Deng CX; Rosell R; Wu YL; Zhong WZ
    Thorac Cancer; 2020 Aug; 11(8):2279-2290. PubMed ID: 32633046
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Acoustic Bioprinting of Patient-Derived Organoids for Predicting Cancer Therapy Responses.
    Chen H; Wu Z; Gong Z; Xia Y; Li J; Du L; Zhang Y; Gao X; Fan Z; Hu H; Qian Q; Ding Z; Guo S
    Adv Healthc Mater; 2022 Jul; 11(13):e2102784. PubMed ID: 35358375
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Patient-derived tumor organoids as a platform of precision treatment for malignant brain tumors.
    Chen CC; Li HW; Wang YL; Lee CC; Shen YC; Hsieh CY; Lin HL; Chen XX; Cho DY; Hsieh CL; Guo JH; Wei ST; Wang J; Wang SC
    Sci Rep; 2022 Sep; 12(1):16399. PubMed ID: 36180511
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Patient-derived organoid models help define personalized management of gastrointestinal cancer.
    Aberle MR; Burkhart RA; Tiriac H; Olde Damink SWM; Dejong CHC; Tuveson DA; van Dam RM
    Br J Surg; 2018 Jan; 105(2):e48-e60. PubMed ID: 29341164
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficient use of patient-derived organoids as a preclinical model for gynecologic tumors.
    Maru Y; Tanaka N; Itami M; Hippo Y
    Gynecol Oncol; 2019 Jul; 154(1):189-198. PubMed ID: 31101504
    [TBL] [Abstract][Full Text] [Related]  

  • 34. From organoids to bedside: Advances in modeling, decoding and targeting of colorectal cancer.
    Betge J; Jackstadt R
    Int J Cancer; 2023 Apr; 152(7):1304-1313. PubMed ID: 36121667
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Organoid technology in cancer precision medicine.
    Xia X; Li F; He J; Aji R; Gao D
    Cancer Lett; 2019 Aug; 457():20-27. PubMed ID: 31078736
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Organoid in colorectal cancer: progress and challenges.
    Ji DB; Wu AW
    Chin Med J (Engl); 2020 Aug; 133(16):1971-1977. PubMed ID: 32826461
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phenotypic heterogeneity of 2D organoid reflects clinical tumor characteristics.
    Fujino S; Ito A; Ohue M; Yasui M; Mizushima T; Doki Y; Mori M; Miyoshi N
    Biochem Biophys Res Commun; 2019 May; 513(2):332-339. PubMed ID: 30955861
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Modeling colorectal cancer: A bio-resource of 50 patient-derived organoid lines.
    Engel RM; Jardé T; Oliva K; Kerr G; Chan WH; Hlavca S; Nickless D; Archer SK; Yap R; Ranchod P; Bell S; Niap A; Koulis C; Chong A; Wilkins S; Dale TC; Hollins AJ; McMurrick PJ; Abud HE
    J Gastroenterol Hepatol; 2022 May; 37(5):898-907. PubMed ID: 35244298
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Patient-Derived Organoids of Colorectal Cancer: A Useful Tool for Personalized Medicine.
    Kiwaki T; Kataoka H
    J Pers Med; 2022 Apr; 12(5):. PubMed ID: 35629118
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Model of Patient-Specific Immune-Enhanced Organoids for Immunotherapy Screening: Feasibility Study.
    Votanopoulos KI; Forsythe S; Sivakumar H; Mazzocchi A; Aleman J; Miller L; Levine E; Triozzi P; Skardal A
    Ann Surg Oncol; 2020 Jun; 27(6):1956-1967. PubMed ID: 31858299
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.